Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2% increase in Q3 revenues to $21.1 billion, beating the Wall Street consensus. Earnings of $2.20 per share were also stronger than what analysts had anticipated.
JNJ shares were down 1.6% immediately following the announcement. The stock has gained 4% since the beginning of this year.
“Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” CEO Alex Gorsky said in a statement.
Prior performance
4Q19 
3Q19
Most Popular
After a weak start to FY25, Conagra Brands (CAG) reaffirms full-year guidance
Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer-packaged goods, reported weaker-than-expected first-quarter results this week, with customers becoming increasingly budget-conscious amid elevated inflation. However, the company said it
Against a weak demand backdrop, what are Lamb Weston’s (LW) plans for the near term?
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) stayed green on Thursday. The stock has dropped 18% over the past three months. The company saw a decline in its revenue
STZ Earnings: All you need to know about Constellation Brands’ Q2 2025 earnings results
Constellation Brands, Inc. (NYSE: STZ) reported its second quarter 2025 earnings results today. Net sales grew 3% year-over-year to $2.91 billion. Comparable sales growth was also 3%. Net loss attributable
